Donor Protein Boosts Survival in Pediatric Bone Marrow Transplants

Pediatric bone marrow transplant patients appear to do much better when the donor's genotype includes a specific natural killer cell protein.

According to Wing Leung, M.D., PhD, of St. Jude Children's Research Hospital and colleagues, pediatric patients receiving an allogeneic hematopoietic stem cell transplantation demonstrated an improved survival of 60 percent and a decrease in disease progression of 62 percent when the donor's cells include the so-called KIR2DL1-R245 polymorphism.

Hope for Transplant Patients

Perhaps the most impressive aspect of this study is that many factors, including reason for transplantation, treatment history and degree of completeness of the HLA match, did not appear to make a difference. In other words, these factors played no part in whether or not the patient benefited from the NK cell protein.

The study, appearing online in the Journal of Clinical Oncology, puts added evidence behind the growing belief that NK cells with KIR2DL1 possess an increased ability to fight cancer cells.

Said Leung:

This approach should dramatically improve the outcome of patients undergoing bone marrow transplantation, regardless of their age or underlying condition. NK cells also play an important role in autoimmune disorders, chronic infections, and other conditions, so these results will likely have an impact beyond cancer.

This was a retrospective study of 313 patients who had an allogeneic transplant at St. Jude between 2000 and 2010. The investigators performed allotyping on DNA samples from the donors.

The patients had a median age of 9.9 years at transplant.

Hematologic malignancies were the reason for transplant in 231 cases. Solid tumors accounted for 25 cases, and "nonmalignant conditions" accounted for the remaining 57.

Source: JCO

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...